Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | SVP, Operations | March 06, 2023 | March 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,862 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Sale · Disposed 831 · Balance 62,862 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 8, 2023 21:26 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 831 | $15.26 | $12,683.97 |
DisclosureSEC source: 0001567619-23-004669 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,862 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 18 | $16.52 | $297.36 |
DisclosureSEC source: 0001567619-23-004274 · doc1.xml · nonDerivative · entry 3 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,693 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 00:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,414 | $15.82 | $22,367.08 |
DisclosureSEC source: 0001567619-23-004274 · doc1.xml · nonDerivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,711 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 47,600 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004544 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 Underlying: Common Stock · 47,600 shares Expires 2033-03-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004544 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,693 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 936 | $16.17 | $15,131.66 |
DisclosureSEC source: 0001567619-23-004274 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,125 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,617 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 20:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,328 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001567619-22-007534 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,615 Underlying: Common Stock · 25,328 shares Expires 2029-11-20 F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on November 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on November 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 20:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 25,328 | $6.52 | $165,138.56 |
DisclosureSEC source: 0001567619-22-007534 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,441 F1 · balance_after: Includes 24,925 restricted stock units. Read SEC document |
| March 23, 2022 Filed Mar 31, 2022 00:02 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,328 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001567619-22-007727 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,615 Underlying: Common Stock · 25,328 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on November 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on November 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 23, 2022 Filed Mar 31, 2022 00:02 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 25,328 | $6.52 | $165,138.56 |
DisclosureSEC source: 0001567619-22-007727 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 24,925 restricted stock units. Read SEC document |
| March 23, 2022 Filed Aug 5, 2022 00:42 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,331 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001567619-22-014989 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,612 Underlying: Common Stock · 15,331 shares Expires 2029-11-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 1/4 of the total shares on November 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on November 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 23, 2022 Filed Aug 5, 2022 00:42 UTC Amendment | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 15,331 | $6.52 | $99,958.12 |
DisclosureSEC source: 0001567619-22-014989 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 24,925 restricted stock units. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 01:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 30 | $16.44 | $493.35 |
DisclosureSEC source: 0001567619-22-006493 · doc1.xml · nonDerivative · entry 3 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,113 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F4 · price: The transaction was executed in multiple trades in prices ranging from $16.44 to $16.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: Includes 24,925 RSUs. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 01:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 993 | $16.86 | $16,741.09 |
DisclosureSEC source: 0001567619-22-006493 · doc1.xml · nonDerivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,143 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F3 · price: The transaction was executed in multiple trades in prices ranging from $16.63 to $17.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006493 · doc1.xml · derivative · entry 4 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:48 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006493 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,136 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 936 | $17.75 | $16,616.53 |
DisclosureSEC source: 0001567619-22-006227 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,836 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · price: The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,001 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 947 shares on May 31, 2021 and 54 shares on November 30, 2021. F4 · balance_after: Includes 14,000 RSUs. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 28,800 | $0.00 Strike: $32.44 | $0.00 |
DisclosureSEC source: 0001567619-21-005730 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 28,800 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005730 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,771 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 16,250 RSUs. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 934 | $34.52 | $32,241.68 |
DisclosureSEC source: 0001567619-21-005541 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,271 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021. F2 · balance_after: Includes 6,750 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 30, 2020 Filed Feb 16, 2021 23:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 264 | $23.05 | $6,085.73 |
DisclosureSEC source: 0001567619-21-004118 · doc1.xml · nonDerivative · entry 2 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,205 F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| May 31, 2020 Filed Feb 16, 2021 23:31 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 941 | $14.45 | $13,597.45 |
DisclosureSEC source: 0001567619-21-004118 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,205 F1 · kind: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. F2 · balance_after: Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0001567619-20-005551 · doc1.xml · derivative · entry 2 Turney Patricia A. · CIK 0001801045 · Senior VP, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common · 27,000 shares Expires 2030-03-27 F3 · derivative.exercise_date: The shares subject to the stock option vest in equal monthly installments over a period of 48 months commencing on the grant date so that 100% of the shares become fully vested and exercisable on February 27, 2024. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 02:10 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005551 · doc1.xml · nonDerivative · entry 1 Turney Patricia A. · CIK 0001801045 · Senior VP, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 9,000 RSUs. The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.